DUPIXENT Breaks New Ground with First Biologic Approval for COPD
Overview of DUPIXENT DUPIXENT (dupilumab) , developed by Sanofi and Regeneron, has added another significant achievement to its portfolio by receiving the first-ever biologic approval for treating Chronic Obstructive Pulmonary Disease (COPD). DUPIXENT, already a blockbuster drug, has been a game-changer in treating various allergic and inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. With its recent approval for COPD, it marks a significant milestone in expanding the treatment landscape for one of the most challenging respiratory diseases. COPD and the Need for New Treatments COPD is a progressive lung disease characterized by obstructed airflow, leading to breathing difficulties, chronic cough, and frequent respiratory infections. It is one of the leading causes of morbidity and mortality worldwide, affecting over 380 million people globally. Until now, treatment options for COPD have been limited to bronchodilators,